A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations

Bex A.;Albiges L.;Staehler M.;Bensalah K.;Giles R. H.;Dabestani S.;Hofmann F.;Hora M.;Kuczyk M. A.;Lam T. B.;Marconi L.;Merseburger A. S.;Fernandez-Pello S.;Tahbaz R.;Abu-Ghanem Y.;Volpe A.;Ljungberg B.;Escudier B.;Powles T.

2018-01-01